News
Enhertu gets FDA nod for tumour-agnostic HER2 cancers
The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors a
